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SUMMARY
Among the cestodes, Echinococcus granulosus, Echinococcus multilocularis and Taenia solium represent the most dangerous
parasites. Their larval stages cause the diseases cystic echinococcosis (CE), alveolar echincoccosis (AE) and cysticercosis,
respectively, which exhibit considerable medical and veterinary health concerns with a profound economic impact. Others
caused by other cestodes, such as species of the generaMesocestoides andHymenolepis, are relatively rare in humans. In this
review, we will focus on E. granulosus and E. multilocularismetacestode laboratory models and will review the use of these
models in the search for novel drugs that could be employed for chemotherapeutic treatment of echinococcosis. Clearly,
improved therapeutic drugs are needed for the treatment of AE and CE, and this can only be achieved through the
development of medium-to-high throughput screening approaches. The most recent achievements in the in vitro culture
and genetic manipulation of E. multilocularis cells and metacestodes, and the accessability of the E. multilocularis genome
and EST sequence information, have rendered the E. multilocularis model uniquely suited for studies on drug-eﬃcacy
and drug target identiﬁcation. This could lead to the development of novel compounds for the use in chemotherapy
against echinococcosis, and possibly against diseases caused by other cestodes, and potentially also trematodes.
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INTRODUCTION
The genus Echinococcus includes seven to nine
described species (Nakao et al. 2007; Varcasia et al.
2008). Of these,Echinococcus multilocularis (the small
fox tapewom) is the most pathogenic, and E. granu-
losus (the small dog tapeworm) represents the most
common species (Thompson, 1986). Both cause life-
threatening diseases of serious public health and
economic concern worldwide (McManus et al. 2003).
Alveolar echinococcosis (AE), caused by E. multi-
locularis, is largely restricted to the Northern hemi-
sphere, such as Central Asia, Russia, Western China,
Europe and Japan. Infections with E. granulosus, the
causative agent of cystic echinococcosis (CE), occur
globally, and mostly in the Mediterranean area,
Central Europe, South America, Africa, Central
Asia, and CE exists as an imported disease in
Western Europe and the USA (Schantz et al. 1995;
Eckert and Deplazes, 2004). 3.6 million disability-
adjusted life years (DALYs) are lost due to CE (Craig
et al. 2007), showing that the impact of the disease is
comparable to onchocercosis and African trypano-
somosis (Budke et al. 2006). AE and CE are diseases
of communities that often lack essential resources,
thus the development of new drugs against these
diseases has not been a major focus of the pharma-
ceutical industry. First, because the population
aﬀected and the number of cases as such do not
represent a promising market. Secondly, there has
been an inherent lack of in vitro culture systems that
would allow cost-eﬀective high-throughput drug
screening. However, the recent achievements in
the establishment of in vitro cultivation systems,
especially for E. multilocularismetacestodes, has now
opened the door for medium-to-high-throughput
drug screening possibilities. These developments
could have considerable impact not only for the
treatment of echinococcosis, but also for other dis-
eases caused by cestodes such as Taenia, Hymeno-
lepis, Mesocestoides and Spirometra and, potentially,
trematodes.
ECHINOCOCCUS: BIOLOGY AND DISEASE
E. multilocularis and E. granulosus share some dis-
tinct features in their life cycle. The adult worms live
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in the intestine of their respective ﬁnal host (dogs for
E. granulosus, foxes, dogs and cats for E. multi-
locularis) where sexual reproduction and subsequent
egg production takes place. Faecal shedding spreads
the eggs into the environment, where they are acci-
dentally taken up by suitable intermediate hosts,
such as small rodents for E. multilocularis, and cattle
and sheep for E. granulosus. These eggs contain the
ﬁrst larval stage, the oncosphere, and during stomach
passage, the oncosphere is activated and leaves the
protective egg. It actively penetrates the intestinal
lining, and migrates via blood and lymphatic vessels
to the visceral organs. These are primarily the liver
for E. multilocularis, and the liver, lung and other
target organs in the case of E. granulosus. There,
these oncospheres develop into metacestodes, which
represent the second larval stage. Within these me-
tacestodes, protoscolex development takes place, and
upon oral uptake by the respective ﬁnal host, proto-
scoleces attach to the intestinal epithelium and de-
velop into adult worms, thus concluding the life cycle
(Rausch, 1995).
Metacestodes of both species are ﬂuid-ﬁlled
vesicles, and represent the disease-causing stage.
They are structured into an inner cellular and an
outer acellular compartment (Fig. 1). The outer,
acellular surface of the metacestode is formed by
the laminated layer, a carbohydrate-rich structure
Fig. 1. SEM of E. granulosus (A,B) and E. multilocularis (C,D) metacestodes. A and C represent lower
magniﬁcation views of broken vesicles, exoposing both the acellular laminated layer (LL) and the germinal layer
(GL); bars=1.5 mm. B and D represent higher magniﬁcation views of the germinal layer of E. granulosus and
E. multilocularis, respectively; bars=400 mm.
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synthesized by the parasite. The laminated layer
covers the entire metacestode surface, and is much
more prominent in E. granulosus metacestodes
(Morseth, 1967; Gottstein and Hemphill, 1997).
The actual larval tissue is formed by the germinal
layer, which itself is composed of a population of
diﬀerent cell types (Figs. 1 and 2). One part consists
of the tegument, which is directly associated with
the inner surface of the laminated layer. It is charac-
terized by microvilli-like extensions, microtriches,
which protrude into the matrix of the laminated
layer and thereby increase the resorbing surface of
the parasite (Fig. 2). In addition, the germinal
layer contains highly diﬀerentiated cell types includ-
ing connective tissue, muscle cells, and glycogen
storage cells, as well as many undiﬀerentiated cells
(Fig. 2).
The fully mature E. granulosus metacestode (i.e.
hydatid cyst) is a single-chambered or septate
unilocular cyst that shows expansive growth and
thereby causes compression of neighbouring tissue,
tissue damage and organ dysfunction (Kern, 2006).
Accidental or traumatic cyst rupture can result in
release of cyst ﬂuid and dissemination of proto-
scoleces, leading to anaphylactic reactions and me-
tastases (secondary echinococcosis) (Stey and Jost,
1993). E. granulosus metacestodes are surrounded
by a host ﬁbrous capsule, the adventitial layer, which
is composed of host connective tissue.
In E. multilocularis infection, metacestode devel-
opment exhibits diﬀerent characteristics. There is
no limiting host-tissue barrier comparable to the
adventitial layer. The metacestode tissue represents
a multivesicular structure that is reproducing
Fig. 2. TEM of E. multilocularis metacestodes cultured in vitro. A shows a low magniﬁcation view of a section through
the metacestode wall, with laminated (LL) and germinal layer (GL); bar=7 mm. B shows a higher magniﬁcation view,
demonstrating LL, GL-tissue with diﬀerent cell types including undiﬀerentiated cells with a large nucleus and
nucleolus (uc), and the tegument with microtriches (arrows); bar=3.2 mm. C and D show higher magniﬁcation views
of longitudinally sectioned (C; bar=0.56 mm) and cross-sectioned (D; bar=0.43 mm) microtriches revealing actin
microﬁlaments as main structural components. Also note the ﬁlamentous meshwork of electron-dense thin ﬁlaments
that is embedded into the matrix of the LL.
Echinococcus metacestodes as laboratory models 571
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S003118200999117X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 15:06:47, subject to the Cambridge Core terms of use, available at
asexually, by formation and budding of daughter
vesicles, with progressive tumour-like growth (Ali-
Khan et al. 1983). This leads to the formation
of a large and heterogenous parasitic mass that is
intermingled with host connective tissue, prolifer-
ative in the periphery, and often necrotic in the
centre (Gottstein and Hemphill, 1997). Metastases
formation may occur in other organs due to the
release of germinal layer cells into the blood or
lymph system (Ali-Khan et al. 1983; Eckert et al.
1983; Mehlhorn et al. 1983). Thus, AE can resemble
a benign malignant tumour (Vuitton, 2009). Proto-
scolex development in humans has been rarely
observed.
BENZIMIDAZOLES FOR THE
CHEMOTHERAPEUTIC TREATMENT OF CYSTIC
ECHINOCOCCOSIS (CE) AND ALVEOLAR
ECHINOCOCCOSIS (AE)
For many years, the preferred treatment strategy for
CE has been radical resection of the parasite mass
(Kern, 2003, 2006). Other options include image-
guide percutaneous treatment (PAIR=puncture,
aspiration, injection, reaspiration) (Brunetti et al.
2004) and chemotherapy (El-On, 2002). Both sur-
gery and PAIR are always accompanied by chemo-
therapy and, for inoperable cases, chemotherapy
remains the only option. These cases include patients
exhibiting cysts in crucial organs such as spine, pelvis
and other sites that are not easily accessible, or
patients with multiple cysts in several organs. The
currently used drugs are mebendazole and albend-
azole. These drugs clearly have the potential to kill
metacestodes, and to cure the patients. Benzimid-
azoles exert their action by binding to tubulin, in-
ducing microtubule depolymerization and inhibiting
polymerization of this essential cytoskeletal element
(reviewed by Hemphill andMu¨ller, 2009). However,
the eﬃcacy of these benzimidazoles depends on size
and type of cyst (benzimidazoles are more eﬀective
against smaller cysts), on the age of the patient (these
drugs work better in younger than in older patients),
and on which organ is aﬀected (e.g. cysts localized in
bones are less susceptible to chemotherapy than
those in liver and lungs). The duration of treatment
plays a crucial role, with prolonged drug adminis-
tration producing the most favourable results for
the patients (Horton, 1997; Franchi et al. 1999;
Vutova et al. 1999). Praziquantel, a heterocyclic
pyrazinoisoquinoline derivative, has been proposed
to be used alongside benzimidazoles in CE-patients.
Praziquantel is well tolerated, less toxic and better
absorbed than albendazole. Praziquantel is used
against the adult stages of Echinococcus and many
other cestodes, and was shown to exhibit a high
eﬃcacy against protoscoleces (Morris et al. 1986) and
metacestodes in animal experiments (Urrea-Paris
et al. 1999, 2001). Themode of action of praziquantel
is a matter of debate. Respective studies were mostly
carried out with schistosomes, where praziquantel
represents the only drug that is currently marke-
ted. Possibilities of praziquantel toxicity include its
actions on nucleoside uptake (Angelucci et al.
2007), inhibition of phospho-inositide turnover
(Wiest et al. 1992), binding to parasite actin (Tallima
and El Ridi, 2007) and the parasite myosin light
chain, and possibly inhibiting its functional activity
(Gnanasekar et al. 2009), interference in glutathione-
S-transferase activity (McTigue et al. 1995), and
stimulation of Ca2+ entry through voltage-operated
Ca2+ channels (VOCCs) (Kohn et al. 2003; Jeziorski
and Greenberg, 2006). The most compelling evi-
dence for the involvement of VOCCs was recently
provided by Nogi et al. (2009) : they used the free-
living ﬂatworm Dugesia japonicum and investigated
regeneration of fragments excised from this plan-
arian that have the ability to reform a complete body
plan, an ability that is driven by a totipotent popu-
lation of stem cells called neoblasts. In the presence
of praziquantel, however, this regeneration process
yielded complete duplication of the entire antierior-
posterior axis, resulting in two-headed organisms
with duplicated nervous and organ systems. This
eﬀect of praziquantel was selectively ablated by
in vivo RNAi of VOCC beta-subunits, but not by
knock-down of alpha-subunits. At higher doses of
praziquantel, knock-down of VOCC beta-subunit
also conferred resistance to praziquantel, conﬁrming
the critical involvement of this beta subunit in the
action of the drug.
A combined treatment regimen with albendazole
and praziquantel given during the month prior to
surgery of E. granulosus-infected patients increased
the number of human patients with non-viable
protoscoleces as compared to therapy with albend-
azole alone (Cobo et al. 1998). Thus, praziquantel
is regarded as useful in cases where cyst content is
spilled during surgery.
For the treatment of AE, surgery and chemo-
therapy are the two only treatment options (Ammann
and Eckert, 1995). Spontaneous cure of AE, leading
to calciﬁed lesions, is possible, but it is not known
how commonly this occurs (Gottstein and Hemphill,
1997; Vuitton, 2009). Radical surgery of viable le-
sions is carried out if possible, but can be diﬃcult
to achieve, and only about one third of all cases are
actually operated on. In contrast to E. granulosus
metacestodes, E. multilocularis metacestodes are
almost exclusively located in the liver. However,
metastases can occur, also involving distant sites
including lungs, spleen and brain. Chemotherapy
should last for at least 2 years post-surgery, and
monitoring of patients should be continued for 10
years. Inoperable cases must undergo long-term
chemotherapy, often life-long (Reuter et al. 2000;
2004; Vuitton, 2009). The experiences with long-
term use of benzimidazoles has had an enormous
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impact on the use of surgery. Generally, palliative
surgery should be avoided and replaced by benzi-
midazole treatment alone or combined with percu-
taneous or perendoscopic interventions to treat
biliary or vascular complications (Bresson-Hadni
et al. 2000, 2006; Vuitton, 2009). Extensive animal
experimentation and clinical experience in human
patients have both demonstrated that albendazole
and mebendazole exhibit a parasitostatic rather than
parasiticidal eﬀect against E. multilocularis meta-
cestodes (Reuter et al. 2004; Vuitton, 2009). Thus
benzimidazoles only prevent parasite growth, and
the recurrence rates after interruption of therapy are
high. Nevertheless, clinical studies have shown that
chemotherapy has signiﬁcantly increased the 10-year
survival rate of inoperable or non-radically operated
AE patients from 6–25% to 80–83% (Hemphill et al.
2007).
Benzimidazoles are generally well tolerated, but
problems can occur. Adverse reactions include
hepatotoxicity, alopoecia, gastrointestinal disturb-
ances and leukopaenia, which is sometimes severe
and irreversible (Horton, 1997). Risks also include
embryotoxicity and teratogenicity. In order to im-
prove bioavailability, liposome-entrapped formu-
lations and emulsions of albendazole have been
tested (Wen et al. 1996; Chai et al. 2004). The use
of cimetidine is discouraged, since it increases in-
testinal absorption (Wen et al. 1996; Schipper et al.
2000), which in turn could result in toxic eﬀects.
Major problems associated with benzimdazoles
are the intra- and inter-individual variations of
the pharmacokinetics, which make it necessary to
measure albendazole sulphoxide and mebendazole
plasma levels on a regular basis in order to adjust
drug dosage and to avoid toxicity (Vuitton, 2009).
This is only possible in specialized facilities, and thus
precludes the use of benzimidazoles in those endemic
areas where eﬃcient drugs would be mostly needed.
In addition, it is unknown whether there is a stage-
speciﬁc response to exposure to benzimidazoles, and
the actual concentration at the site where the drug
exerts its action is not known.These pharmacological
uncertainties, together with the diﬃculties in assess-
ing metacestode viability in humans, show that
novel and improved chemotherapeutical tools are
needed in order to optimize the treatment of CE
and AE.
THE ROLE OF IN VITRO CULTURE IN DRUG
DISCOVERY
In order to identify novel potential alternatives for
chemotherapy against echinococcosis, the strategy
used most commonly has been whole organism
screening of E. multilocularis and E. granulosus
metacestodes and/or protoscoleces. In most cases,
researchers have focused on broad-spectrum anti-
infective agents and anti-cancer compounds, many
of which also exhibited reasonable eﬃcacy against
Echinococcus (Hemphill and Mu¨ller, 2009).
In vitro chemotherapy studies on CE have
mostly, but not exclusively, been carried out on
protoscoleces, since these are easily obtained from
cysts of an infected animal. The metabolism, and
thus drug-susceptibility, of E. granulosus proto-
scoleces might however be diﬀerent from the meta-
cestode stage tissue. As an example, praziquantel is
highly active against adult tapeworms and against
protoscoleces, but only of limited eﬃcacy against
metacestodes. Conversely, albendazole is less active
against protoscoleces, but of signiﬁcantly higher
eﬃcacy against metacestodes (Taylor et al. 1989).
Infection of laboratory animals with E. granulosus
protoscoleces results in the development of meta-
cestodes, which mimics the process of secondary
hydatid disease in humans, and this diﬀerentiation
process can also be achieved in vitro (Walker et al.
2004). E. granulosus metacestodes do not proliferate
in vitro but, as in vivo, show amarked increase in size.
Thus, extensive animal experimentation is necessary
for constant supply of metacestode material. In
contrast, E. multilocularis metacestodes, besides in-
creasing in size, also proliferate asexually and, pro-
vided with the corresponding nutrients and growth
factors, will form new vesicles either endogenously
(from within the germinal layer) or exogenously
(by budding of daughter metacestodes from older
vesicles ; Fig. 3). Thus, the fact that E. multilocularis
metacestodes proliferate in vitro has rendered this
model suitable for the experimental assessment of
the eﬀects of chemotherapeutically interesting com-
pounds.
Historically, the in vitro culture of E. multilocularis
metacestodes was achieved by dissection of infected
rodents and placing small pieces of infected tissue
or vesicle suspension into a suitable culture medium
at 37 xC. After a few weeks, newly formed me-
tacestodes emerged, which were infective when
re-introduced back into rodents (Hemphill and
Gottstein, 1995). These were co-culture systems, as
parasites could be maintained for several months in
the presence of feeder cells, and in the absence of
feeder cells, metacestodes degenerated within a few
weeks. Jura et al. (1996) introduced a second in vitro
co-culture system, which was based on co-incubation
of homogenized parasite tissue obtained from in-
fected rats with primary rat hepatocytes embedded in
a collagen layer. Although useful in many instances
(reviewed in Hemphill et al. 2002, 2007; Brehm and
Spilitois, 2008a), these co-culture systems provided
only moderate yields and only a very limited number
of drugs could be studied. Thus, the amount of
metacestodes that could be generated was not suf-
ﬁcient for larger scale investigations.
Recently, Spiliotis and Brehm (2008) have over-
come this problem and established a large-scale
cultivation system which utilizes homogenized
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metacestode tissue that is incubated in liquid culture
together with rat hepatoma feeder cells. Using this
system, high numbers of metacestodes with com-
parable sizes can be generated within a few weeks
of incubation. Thus, a major task of feeder cells ap-
pears to be the provision and secretion of growth
factors that are needed by the parasites to undergo
proliferation, growth and diﬀerentiation. E. multi-
locularis metacestodes possess several receptors that
interact with human epidermal growth factor (EGF),
insulin, transforming growth factor-beta and steroid
hormones (Brehm et al. 2006; Brehm and Spiliotis,
2008b), and these most likely allow the parasite to
communicate with its host and adapt to alterations
in living conditions, regulating gene expression to
its favour. Of course, these receptors, and associated
signalling pathways within the parasite, represent
interesting targets for potential chemotherapeutical
intervention (Brehm et al. 2006; Gelmedin et al.
2008). In addition, Spiliotis et al. (2004) developed
the methodology to culture E. multilocularis meta-
cestodes axenically, in the absence of feeder cells,
under reducing and anaerobic conditions. In the
presence of oxygen, these metacestodes degenerate
within few weeks (Spilitois et al. 2004), illustrating
the high sensitivity of E. multilocularis metacestodes
to oxygen intermediates. The speciﬁc adaptation of
the mitochondrial respiratory system to anaerobic
environments has been shown also for E. multi-
locularis protoscoleces (Matsumoto et al. 2008).
Thus, another important task of feeder cells is to
remove toxic oxygen intermediates (Brehm and
Spiliotis, 2008a).
METHODS FOR THE ASSESSMENT OF
ANTI-ECHINOCOCCAL DRUG CANDIDATES
By using animal experimentation, the primary as-
sessment of anti-echinococcal drug candidates has
often been performed in mice or gerbils, through
evaluation of parasite mass and/or health parameters
of the host. This has led to the extensive use of animal
experimentation, but has often yielded inconclusive
results (reviewed in Siles-Lucas and Hemphill,
2002). More recently, in vitro cultured Echinococcus
metacestodes have been increasingly used for
the primary assessment of drug susceptibilities
(Hemphill et al. 2002, 2007).
A major problem associated with drug-eﬃcacy
assessment has always been the monitoring of the
actual metacestode viability following in vitro drug
treatment. In a primary evaluation, the eﬀects of
in vitro drug treatment can be assessed mainly by
visual inspection of morphological alterations and
light-microscopy. SEM and TEM have also been
used extensively to investigate tissue damage in
more detail (Ingold et al. 1999; Stettler et al. 2003;
Naguleswaran et al. 2006; Spicher et al. 2008a ; see
also Fig. 2E, F), and nuclear magnetic resonance
spectroscopy (NMR) has been applied to investigate
metabolic changes imposed upon the parasites by
drug treatments (Ingold et al. 1999). Others have
Fig. 3. Exogenous and endogenous proliferation of E. multilocularis metacestodes in vitro. Exogenous outgrowth
of a newly formed vesicle (arrows in A–B) from a pre-exisiting parent vesicle appears to be followed by budding oﬀ
of the daughter vesicle (C). Vesicles are also formed within older metacestodes, most likely by emerging out of
the germinal layer, and these smaller metacestodes are released upon desintegration of the older metacestode (D,E).
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attempted to assess parasite viability and growth
by the quantiﬁcation of the expression of mol-
ecular marker genes such as 14-3-3 and II/3-10
(Matsumoto et al. 2006). Visual inspection relies on
subjective observations and thus requires experi-
enced personnel, while other techniques such as
SEM, TEM, NMR and RT-real time PCR are in-
trinsically time-consuming and expensive. Although
these approaches have lead to the identiﬁcation of
several compounds with reasonable activities in the
micromolar range in vitro (see below), it has not been
possible to implement these techniques in a cost-
eﬀective manner at a larger scale, and they have not
always produced conclusive results. For instance, in
vitro culture of E. multilocularis metacestodes in
the presence of albendazole sulphoxide for 14 days
resulted in altered composition of vesicle ﬂuid
metabolites as assessed by NMR, and complete
destruction of the metacestode structural integrity as
visualized by SEM and TEM (Ingold et al. 1999).
However, bioassay (re-inoculation of treated parasite
material into mice) subsequently showed that the
parasite had not been killed completely (Stettler et al.
2003). This was conﬁrmed by Reuter et al. (2006),
and illustrates the diﬃculties in viability assessment
following drug treatment.
Although several potentially interesting com-
pounds were identiﬁed, and combinations of some of
these drugs with albendazole led to slightly improved
treatment eﬃcacy in experimentally infected mice
or gerbils, none of these compounds exhibited im-
proved activities compared to albendazole (reviewed
in Hemphill et al. 2007). Thus, many more drugs
and/or compound classes should be investigated, and
there is an urgent need for a reliable, but also easy-
to-handle and rapid in vitro drug screening assay
for the identiﬁcation of chemotherapeutically inter-
esting compounds in vitro.
Attempts to develop screening assays based on the
use of vital dyes employed for the assessment of cell
viability, such as Alamar blue and Trypan blue, were
undertaken. They worked well for protoscolex
viability asessment (Walker et al. 2004), but they
were not practical when used with metacestodes,
as these dyes tend to bind to components of the
laminated layer (M. Spicher et al. unpublished
observations). The MTT viability assay, which is
based on the activity of mitochondrial reductase
that reduces yellow 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromide to purple formazan
in living cells, worked well for E. multilocularis me-
tacestodes in an experimental setting (Emery et al.
1995), but was not found to be useful for the assess-
ment of larger numbers of compounds (A. Hemphill,
unpublished observations).
Another biomarker-based approach to develop
such a screening assay could be to identify speciﬁc
enzyme activities in culture supernatant obtained
from drug-treated parasites, which release vesicle
ﬂuid components once they are damaged or struc-
turally impaired upon exposure to an active com-
pound. Such biomarkers indicating damage are not
present in culture supernatants of untreated meta-
cestodes. E. multilocularis metacestodes are basically
ﬂuid-ﬁlled vesicles that are surrounded by an outer,
acellular laminated layer, and the inner surface of
this laminated layer is delineated by the actual
parasite tissue, the germinal layer. The germinal
layer secretes the components of the laminated layer
towards the metacestode periphery into the lami-
nated layer, and also secretes and/or releases meta-
bolites into the vesicle ﬂuid. One enzyme that
represents an intrinsic component of the vesicle ﬂuid,
and which is also found on the laminated layer,
is alkaline phosphatase (AP; Sarciron et al. 1991;
Lawton et al. 1997). The detection of AP activity in
medium supernatants of drug-treated metacestode
cultures has been proposed as a method to screen
for active drugs (Stettler et al. 2001). AP-activity
was indeed increased in culture supernatants of
metacestodes treated with nitazoxanide (Stettler
et al. 2003), 2-methoxyestradiol and artemisinin-
derivatives (Spicher et al. 2008a, b), but the sensi-
tivity of this assay was not always satisfactory
(Gelmedin et al. 2008; A. Hemphill, unpublished
observations). Thus, detection of AP activity does
not represent a reliable measure for drug screening
in vitro. Another enzyme, phosphoglucose isomer-
ase, released by dying E. multilocularismetacestodes,
was found to be a promising marker that allows
assessment of parasite viability of drug-treated
E. multilocularis metacestodes. The potential of this
screen for high-throughput assays will be published
soon (B.Stadelmann etal. unpublishedobservations).
Parasite-derived biomarkers could also play a
major role for monitoring drug eﬃcacy in patients
suﬀering from echinococcosis during drug trials. For
instance, it was previously shown that the serological
response of patients against E. multilocularis alkaline
phosphatase could reﬂect viability following surgery
and/or chemotherapy (Sarciron et al. 1997). Such
immunological tests are dependent on the availability
and speciﬁcity of antigens and do not always provide
clear-cut results; the same applies to molecular tests,
such as PCR, which require speciﬁc primers. Thus,
more recently, disease-speciﬁc biomarkers have
been identiﬁed by metabolic proﬁling emplyoing 1H
nuclear magnetic resonance spectroscopy (NMR).
This technology delivers an overview of the meta-
bolic composition of bioﬂuids and tissues in diseased
versus non-diseased individuals, and such studies
have provided the means for detection and diﬀeren-
tiation of e.g. coronary heart disease and schizo-
phrenia (Ordovas and Moser, 2006; Holmes et al.
2006). Metabolic proﬁling has been carried out in
rodents infected with S. mansoni (Wang et al. 2004),
S. japonicum (Wang et al. 2006), T. spiralis (Martin
et al. 2006), Trypanosoma brucei brucei (Wang et al.
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2008), Plasmodium berghei (Li et al. 2008), and
Echinostoma caproni (Saric et al. 2008), and could be
of high interest for other infections where good
markers for disease progression and/or regression are
still missing. For instance, a recent study (Hosch
et al. 2008) has shown that there is a good correlation
between metabolic viability assessment achieved
through 1H NMR of E. granulosus cyst ﬂuid
measured ex vivo from 50 patients with diﬀerent
degrees of disease classiﬁcation and the classical
ultrasound/light microscopy disease assessment,
demonstrating the potential beneﬁt of the use of
metabolic biomarkers in disease and parasite viability
assessments, e.g. during chemotherapy.
DRUG CANDIDATES FOR THE TREATMENT
OF ECHINOCOCCOSIS
Cystic echinococcosis (CE)
A selection of drugs and potential drug candidates
against CE is provided in Table 1. In many in-
stances, in vitro studies on compounds active against
E. granulosus have employed protoscoleces. Exper-
imental prophylactic therapy of E. granulosus
protoscoleces was carried out as a model that would
mimic spillage during surgery, by treating proto-
scoleces with praziquantel (Urrea-Paris et al. 2001)
or a combination of praziquantel and albendazole
(Casado et al. 2001) prior to injection into mice. The
combination of albendazole and praziquantel has
been used successfully in the treatment of human CE
(Cobo et al. 1998). Other promising compounds with
in vitro protoscolicidal actions against E. granulosus
were cetrimide (Frayha et al. 1981) and the iono-
phore monensin (Rogan and Richards, 1986), but
these drugs were rather ineﬀective against metaces-
todes. Levamisole and ivermectin, which are classi-
cally used against nematode infections, exhibited
in vitro activities similar to benzimidazoles (Martinez
et al. 1999; Elissondo et al. 2009). The direct injec-
tion of ivermectin into E. granulosus cysts in laparo-
tomised patients has also shown parasiticidal eﬀects
(Ochieng’-Mitula and Burt, 1996). The combination
of ivermectin plus albendazole has shown synergistic
eﬀects in infected mice (Moreno et al. 2002). Benzi-
midazoles vary considerably with regard to their
protoscolicidal action. Albendazole and albendazole
sulphoxide have been shown to be active against
E. granulosus protoscoleces in vitro (Chinnery and
Morris, 1986;Morris et al. 1987; Perez-Serrano et al.
1994), but the in vitro protoscolicidal action of these
drugs is rather slow and requires a longer incubation
period compared tomebendazole (Morris et al. 1987;
Rodriguez-Caabeiro et al. 1989) or oxfendazole, the
major fenbendazole sulphoxide metabolite. Against
E. granulosus infection in rodents, a combination
of fenbendazole and netobimin (Garcia-Llamazarez
et al. 1997) showed synergistic eﬀects, allowing theT
ab
le
1
.
A
se
le
ct
io
n
o
f
d
ru
g
ca
n
d
id
at
es
ag
ai
n
st
cy
st
ic
h
y
d
at
id
d
is
ea
se
ca
u
se
d
b
y
E
ch
in
oc
o
cc
u
s
gr
a
n
u
lo
su
s.
C
o
m
p
o
u
n
d
In
v
it
ro
ac
ti
v
it
y
In
v
iv
o
ac
ti
v
it
y
A
ct
iv
it
y
in
h
u
m
an
s
R
ef
er
en
ce
s
M
eb
en
d
az
o
le
,
al
b
en
d
az
o
le
Y
es
–
cy
st
s,
p
ro
to
sc
o
le
ce
s
Y
es
–
ro
d
en
ts
,
sh
ee
p
Y
es
R
ev
.
in
S
il
es
-L
u
ca
s
an
d
H
em
p
h
il
l,
2
0
0
2
O
x
fe
n
d
az
o
le
N
o
t
as
se
ss
ed
Y
es
–
sh
ee
p
,
g
o
at
s
U
n
d
er
li
ce
n
se
B
la
n
to
n
et
a
l.
1
9
8
8
;
D
u
eg
er
et
a
l.
1
9
9
9
;
G
av
id
ia
et
a
l.
2
0
0
9
F
lu
b
en
d
az
o
le
Y
es
–
cy
st
s,
p
ro
to
sc
o
le
ce
s
Y
es
–
ro
d
en
ts
Y
es
E
ll
is
so
n
d
o
et
a
l.
2
0
0
6
;
2
0
0
7
A
lb
en
d
az
o
le
+
p
ra
zi
q
u
an
te
l
Y
es
–
p
ro
to
sc
o
le
ce
s
N
o
t
as
se
ss
ed
Y
es
C
o
b
o
et
a
l.
1
9
9
8
;
C
as
ad
o
et
a
l.
2
0
0
1
A
lb
en
d
az
o
le
+
iv
er
m
ec
ti
n
Y
es
–
cy
st
s,
p
ro
to
sc
o
le
ce
s
Y
es
–
ro
d
en
ts
N
o
t
as
se
ss
ed
M
o
re
n
o
et
a
l.
2
0
0
2
;
E
li
ss
o
n
d
o
et
a
l.
2
0
0
9
F
en
b
en
d
az
o
le
+
n
et
o
b
im
in
N
o
t
as
se
ss
ed
Y
es
–
ro
d
en
ts
N
o
t
as
se
ss
ed
G
ar
ci
a-
L
la
m
az
ar
ez
et
a
l.
1
9
9
7
C
et
ri
m
id
e
Y
es
–
p
ro
to
sc
o
le
ce
s
Y
es
–
sh
ee
p
,
ca
tt
le
(i
n
tr
ac
y
st
)
N
o
t
as
se
ss
ed
F
ra
y
h
a
et
a
l.
1
9
8
1
M
o
n
en
si
n
Y
es
–
p
ro
to
sc
o
le
ce
s
N
o
t
as
se
ss
ed
N
o
t
as
se
ss
ed
R
o
g
an
an
d
R
ic
h
ar
d
s,
1
9
8
6
L
ev
am
is
o
le
Y
es
–
p
ro
to
sc
o
le
ce
s
N
o
t
as
se
ss
ed
N
o
t
as
se
ss
ed
M
ar
tı´
n
ez
et
a
l.
1
9
9
9
Iv
er
m
ec
ti
n
Y
es
–
cy
st
s,
p
ro
to
sc
o
le
ce
s
N
o
–
ro
d
en
ts
Y
es
–
sh
ee
p
(i
n
tr
ac
y
st
)
N
o
t
as
se
ss
ed
O
ch
ie
n
g
’-
M
it
u
la
an
d
B
u
rt
,
1
9
9
6
;
M
ar
ti
n
ez
et
a
l.
1
9
9
9
;
M
o
re
n
o
et
a
l.
2
0
0
2
;
E
li
ss
o
n
d
o
et
a
l.
2
0
0
9
N
it
az
o
x
an
id
e
Y
es
–
cy
st
s,
p
ro
to
sc
o
le
ce
s
N
o
-
sh
ee
p
Y
es
–
ac
ti
v
e
ag
ai
n
st
p
ro
g
re
ss
iv
e
d
is
ea
se
W
al
k
er
et
a
l.
2
0
0
4
;
G
av
id
ia
et
a
l.
2
0
0
9
;
W
in
n
in
g
et
a
l.
2
0
0
9
T
h
y
m
o
l
Y
es
-p
ro
to
sc
o
le
ce
s
N
o
–
ro
d
en
ts
N
o
t
as
se
ss
ed
K
am
m
er
er
an
d
P
er
ez
-E
sa
n
d
i,
1
9
7
5
;
E
li
ss
o
n
d
o
et
a
l.
2
0
0
8
C
y
cl
o
sp
o
ri
n
A
Y
es
–
p
ro
to
sc
o
le
ce
s
Y
es
–
ro
d
en
ts
N
o
t
as
se
ss
ed
H
u
rd
et
a
l.
1
9
9
3
;
C
o
le
b
ro
o
k
et
a
l.
2
0
0
4
G
en
is
te
in
an
d
d
er
iv
at
es
Y
es
–
p
ro
to
sc
o
le
ce
s
N
o
t
as
se
ss
ed
N
o
t
as
se
ss
ed
N
ag
u
le
sw
ar
an
et
a
l.
2
0
0
6
D
ih
y
d
ro
ar
te
m
is
in
in
,
ar
te
su
n
at
e
Y
es
–
cy
st
s
N
o
t
as
se
ss
ed
N
o
t
as
se
ss
ed
S
p
ic
h
er
et
a
l.
2
0
0
8
b
A. Hemphill and others 576
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S003118200999117X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 15:06:47, subject to the Cambridge Core terms of use, available at
administration of lower drug dosages. Oxfendazole,
like albendazole, is a benzimidazole, used in veter-
inary medicine for the treatment of nematode infec-
tions, and has a similar antimicrobial spectrum
but a longer half-life. Experimental treatments of
naturally E. granulosus-infected sheep and goats
suggested that oxfendazole may be as eﬃcacious as
albendazole, but does not require daily uptake of
the drug because of its prolonged bioavailability
(Blanton et al. 1988; Dueger et al. 1999). Nitazo-
xanide, a nitro-thiazole-analogue (Hemphill et al.
2006) induced severe damage to E. granulosus
protoscoleces and the germinal layer of E. granulosus
metacestodes within few days of in vitro culture
(Walker et al. 2004). Nitazoxanide treatment was not
eﬀective against experimental E. granulosus infection
in sheep, but oxfendazole treatment, and a combi-
nation of oxfendazole and nitazoxanide, signiﬁcantly
decreased the number of fertile cysts and increased
the number of degenerated cysts (Gavidia et al.
2009). On the other hand, a recent case report has
suggested beneﬁcial eﬀects of nitazoxanide in the
treatment of refractory bony hydatid disease in a
human patient (Winning et al. 2009). This patient
had been suﬀering from progressive disease despite
treatment with albendazole and praziquantel, and the
clinical response on nitazoxanide treatment showed
marked improvement in the soft tissue cysts, with
stable disease in the bony pelvis. Although further
studies are required, this report suggests that nita-
zoxanide may be an eﬀective treatment option in CE,
particularly in patients with progressive disease who
are receiving conventional treatment (Winning et al.
2009).
Profound protoscolicidal activity was also reported
for another benzimidazole-derivative, ﬂubendazole
(Ellissondo et al. 2006, 2009). Further studies sub-
sequently showed that ﬂubendazole also exhibited
anti-E. granulosus metacestocidal activities in vitro
and in vivo in experimentally infected mice
(Elissondo et al. 2007). The same authors, together
with Kammerer and Perez-Esandi (1975), showed
that thymol, one of the major components of the
essential oils of Thymus, was found to exhibit sub-
stantial protoscolicidal activity (Elissondo et al.
2008).
Cyclosporin A, employed mainly as an immuno-
suppressant during the management of organ trans-
plants, also exhibits anti-echinococcal activity. The
administration of cyclosporin A in ﬁve consecutive
daily doses, beginning 2 days prior to the infection
of mice withE. granulosus protoscoleces, resulted in a
signiﬁcant reduction in cyst numbers and cystmasses
measured at 20 weeks after infection. However, no
changes in cyst mass and numbers were recorded
when the drug was administered 18 weeks after
infection, but the wet weight was decreased by
42% compared with untreated controls. Ultrastruc-
tural examination of the germinal membrane and
laminated layer of late-treated E. granulosus revealed
abnormalities in all cysts studied whereas control and
early-treated hydatids were normal (Hurd et al.
1993). Cyclosporin A has also been shown to aﬀect
E. granulosus protoscoleces in vitro (Colebrook et al.
2004).
Alveolar echinococcosis (AE)
A selection of drugs and potential drug candidates
for the treatment of AE is provided in Table 2.
Cyclosporin A, contrary to what was found in CE,
lacked anti-parasitic activity against E. multilocularis
infection in experimentally infected mice (Liance
et al. 1992). Doxorubicin, or hydroxyldaunorubicin,
a DNA-interacting drug used widely in the treat-
ment of a wide range of cancers (Launchbury
and Habboubi, 1993), was bound to poly-
isohexylcyanoacrylate nanoparticles (a colloidal
biodegradable drug carrier) and applied in E. mutli-
locularis-infected mice, resulting in the reduction
of the development of the parasite in the liver and a
reduced viability of the metacestode. Free doxo-
rubicinorunboundnanoparticleshadnoantiparasitic
activity (Liance et al. 1993). Animal experimentation
in rodents demonstrated parasitostatic eﬀects of
mytomicin C, piperazine and quinolone derivates,
alkylaminoethers and propargylic alcohols, either
at a lower level or comparable to benzimidazoles
(reviewed in Siles-Lucas and Hemphill, 2002). The
eﬃcacy of praziquantel was inadequate (Marchiondo
et al. 1994), although showing some eﬀects on pro-
toscoleces in vitro (Taylor and Morris, 1988). Also,
the treatment of E. multilocularis-infected mice with
alpha-diﬂuoromethylornithine was not successful
(Miyaji et al. 1993).
More recently, studies on chemotherapeutically
interesting compounds have employed in vitro
cultured parasites. Nitazoxanide, a broad-spectrum
anthelminthic also used for treatment against enteric
bacteria, Giardia and Cryptosporidium (Hemphill
et al. 2006), was identiﬁed as a compound inducing
signiﬁcant distortion of the germinal layer in vitro,
and nitazoxanide-treated E. multilocularis meta-
cestodes were non-viable when introduced into
susceptible mice (Stettler et al. 2003). Reuter et al.
(2006) investigated the in vitro eﬃcacy of a series of
compounds against E. multilocularis metacestodes,
including albendazole, artemether, caspofungin,
itraconazole, ivermectin, methiazole, miltefosine,
nitazoxanide, rifampicin and trimethoprim/sulfa-
methoxazole. They found that albendazole, itra-
conazole, methiazole and nitazoxanide eﬀectively
destroyed parasite vesicles in vitro. However, after
drug discontinuation, re-growth of vesicles occurred,
indicating a parasitostatic eﬀect only. Combination
treatment with albendazole/nitazoxanide at con-
centrations between 1 and 10 mg/ml for 3 weeks
yielded no re-growth of parasites during 8 months of
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Table 2. A selection of drug candidates against alveolar echinococcosis caused by Echinococcus multilocularis
Compound In vitro activity In vivo activity Activity in humans References
Cyclosporin A Not assessed No – rodents Not assessed Liance et al. 1992
Doxorubicin and colloidal carrier Not assessed Yes – rodents Not assessed Liance et al. 1993
Mitomycin C, piperazine and derivates,
alkylaminoethers, propargylic alcohols
Not assessed Yes – rodents Not assessed Rev. in Siles-Lucas and Hemphill, 2002
Praziquantel Yes – protoscoleces No – rodents Not assessed Taylor and Morris, 1988; Marchiondo et al. 1994
Mebendazole, albendazole* Yes – metacestodes,
protoscoleces
Yes – rodents Yes Rev. in Siles-Lucas and Hemphill, 2002
Flubendazole Not assessed Yes – rodents No Rev. in Siles-Lucas and Hemphill, 2002
Itraconazole*, methiazole* Yes – cysts Not assessed Not assessed Reuter et al. 2006
a-diﬂuoromethyl-ornithine Not assessed No – rodents Not assessed Miyaji et al. 1993
Nitazoxanide* or
nitazoxanide+albendazole
Yes – metacestodes Yes – rodents Only case reports.
Nitazoxanide alone not eﬀective.
Some limited activity in
combination with albendazole.
Needs more studies
Stettler et al. 2003, 2004; Reuter et al. 2006;
Kern et al. 2008
Artemether, caspofungin,
ivermectin, miltefosine,
rifampicin, trimethoprim
/sulfamethoxazole
No – metacestodes Not assessed Not assessed Reuter et al. 2006
Amphotericin B desoxycholate* Yes – metacestodes Not assessed Yes (intravenous) Reuter et al. 2003a, b
Genistein and derivates Yes – metacestodes Not assessed Not assessed Naguleswaran et al. 2006
Pyridinyl imidazoles Yes – metacestodes Not assessed Not assessed Gelmedin et al. 2008
2-Methoxyestradiol Yes – metacestodes No – rodents Not assessed Spicher et al. 2008a
Dihydroartemisinin, artesunate Yes – metacestodes No- rodents Not assessed Spicher et al. 2008b
Isoprinosine and derivates Yes – protoscoleces Yes – rodents Not assessed Lawton et al. 2001
* Parasitostatic
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drug discontinuation, and the subsequent evaluation
in a bioassay in gerbils did also not result in viable
parasite infections. In this respect, Stettler et al.
(2004) showed that nitazoxanide, applied orally to
E. multilocularis infected mice, either alone or in
combination with ABZ, exhibited a profound anti-
parasitic eﬃcacy, with the albendazole/nitazoxanide
combination yielding the most promising outcome in
terms of reducing parasite weight. The pharmaco-
kinetic analysis of corresponding serum levels in
mice showed that the application of albendazole in
combination with nitazoxanide increased consider-
ably the levels and the half-life of albendazole sul-
foxide (Stettler et al. 2004). Therefore, the increased
eﬃcacy observed in mice could be the result of an
increased availability of albendazole sulfoxide in
mice receiving the combination treatment. Despite
these promising results, neither nitazoxanide mono-
therapy nor nitazoxanide-albendazole combination
therapies were highly eﬀective in human patients
suﬀfering from AE (Kern et al. 2008).
Amphotericin B desoxycholate (cAMB), an anti-
fungal compound, eﬀectively inhibited the growth
of E. multilocularis metacestodes, ﬁrst in vitro, and
subsequently in human patients in vivo (Reuter
et al. 2003a, b). A major limitation of cAMB is its
mode of administration (intra-venous), which makes
it unsuitable for prolonged use, except for salvage
treatment (Reuter et al. 2003b). Also, the action of
cAMB is only parasitostatic and, since the drug is
nephrotoxic, its widespread use is limited. Never-
theless, prolonged application of cAMB for months
to years may be feasible in some cases, as side eﬀects
are mild and serious organ damage does not appear
to occur (Reuter et al. 2003b).
In vitro studies on E. multilocularis metacestodes
and E. granulosus protoscoleces have shown that
genistein, representing a major component of soya
and the most prominent isoﬂavonoid, as well as
a number of genistein derivatives, are also highly
eﬀective against these parasites. The molecular basis
of the eﬃcacy of genistein and its derivative Rm6423
have not yet been elucidated, but these compounds
could interfere in signalling, for instance, through an
inhibition of the tyrosine kinase activity associated
with the epidermal growth factor receptor identiﬁed
in E. multilocularis (see Brehm et al. 2006). Recently,
Gelmedin et al. (2008) identiﬁed pyridinyl imida-
zoles as ATP-competitive inhibitors of a p38-like
mitogen-activated protein kinase (MAPK) of E.
multilocularis by adding them to in vitro cultures,
demonstrating death of parasite vesicles at con-
centrations that did not aﬀect cultured mammalian
cells.
An endogenous metabolite of oestrogen with
both anti-angiogenic and anti-tumour eﬀects, 2-
methoxyestradiol (2-ME) (reviewed by Schumacher
and Neuhaus, 2001) was shown to induce severe
damage to E. multilocularismetacestodes in vitro in a
dose-dependent manner (Spicher et al. 2008a).
However, 2-ME-treatment of experimentally in-
fected mice did not result in a reduction in parasite
weight compared to the control, demonstrating that
in vitro and in vivo situations are not always com-
parable. Best results were achieved with a treatment
using a combination of 2-ME and albendazole, which
lead to a reduction in parasite weight compared to
albendazole treatment alone, but results did not show
statistical signiﬁcance (Spicher et al. 2008a). In vitro
treatment of E. multilocularis and E. granulosus
larval stages with the antimalarials dihydroarte-
misinin and artesunate exhibited promising results,
while 6 weeks of in vivo treatment of mice with in-
fected E. multilocularis metacestodes had no eﬀect.
Again, combination treatments of both drugs with
albendazole led to a substantial but statistically not
signiﬁcant reduction in parasite weight compared to
results with albendazole alone (Spicher et al. 2008b).
The in vitro eﬀect of isoprinosine and its derivates
has also been demonstrated against protoscoleces of
E. multilocularis (Lawton et al. 2001).
RELEVANCE OF ECHINOCOCCUS METACESTODE
SCREENING MODELS FOR OTHER CESTODES
AND TREMATODES
Numerous studies have demonstrated that many
of those drugs that were active in E. granulosus
drug screening models were also of signiﬁcant
relevance for E. multilocularis and vice versa (see
above). In addition, there is ample evidence that
most compounds with good in vitro and in vivo eﬃ-
cacy against Echinococcus metacestodes are also of
relevance for combatting infections by other cestode
larval stages. For instance, cysticerci of T. taeniae-
formis were highly sensitive to praziquantel (Becker
et al. 1981), and the same applied to T. solium
and T. pisiformis (Garcia-Dominguez et al. 1991;
Martinez Zedillo et al. 1992). Albendazole and
mebendazole (or modiﬁed derivatives) were also
active against T. taeniaeformis cysticerci in exper-
imentally infected mice (Verheyen et al. 1978; Jain
et al. 1989). To date, albendazole and praziquantel,
taken as short-term treatments (8–15 days) are the
main drugs of choice for chemotherapeutic treatment
of neurocysticercosis in humans (Garcia et al. 2003;
Shandera and Kass, 2006). A recent in vitro study
on T. crassiceps indicates that a combination of
nitazoxanide and albendazole could be used for the
treatment of cysticercosis infections (Palomares-
Alonso et al. 2007), but in vivo evidence is still
lacking. The eﬀects of other benzimidazoles, such as
ﬂubendazole, were evaluated in T. solium-infected
swine, with promising results (Tellez-Giron et al.
1981) that were subsequently conﬁrmed in human
patients (Tellez-Giron, 1984).
The activity of benzimidazole derivatives against
Hymenolepis larvae was evaluated in the intermediate
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host Tribolium confusum, demonstrating clear eﬀects
with regard to larval development (Novak and
Blackburn, 1985). However, in the rodent model it
was shown that benzimidazole drugs were only
eﬀective against H. nana oncosphere infection, but
already developed cysticercoids were diﬃcult to
cure (Gupta et al. 1981; Maki and Yanagisawa,
1985), and neither ﬂubendazole nor thiabendazole
could clear H. nana cysticercoid infections in mice.
Mebendazole and a series of modiﬁed benzimidazole
derivatives were eﬀective against H. nana and
H. diminuta cysticercoids (Dubey et al. 1985).
In vitro studies on the eﬀects of exposure of
Mesocestoides corti tetrathyridia to anti-parasitic
drugs revealed that liposomized praziquantel and
albendazole had a deleterious eﬀect on the parasite
morphology and development (Hrckova et al. 1998;
Britos et al. 2000; Saldana et al. 2001). The eﬃcacy
and mode of action of praziquantel were studied in
the mouse model, showing that application of prazi-
quantel had an adverse eﬀect on the tetrathyridia
burden in the liver and peritoneum (Hrckova and
Velebny, 1995, 1997). Following the oral adminis-
tration of mebendazole to M. corti-infected mice, a
parasiticidal eﬀect was observed (Heath et al. 1975;
Eckert and Pohlenz, 1976). This is in contrast to
other cestode larvae, against which mebendazole
exerts a parasitostatic eﬀect only. Deleterious actions
of other drugs on Mesocestoides tetrathyridia, in-
cluding cyclosporin A (Chappell et al. 1989) and
albendazole (Terenina et al. 1998), have also been
reported.
Potentially, the Echinococcus screening models
could also have some, albeit limited, relevance for a
number of trematode species, including Schistosoma
japonicum, S. manoni, Chlonorchis sinensis, Fasciola
hepatica and Opistorchis viverrini. For instance,
praziquantel is the drug of choice for the treatment
of schistosomiasis (King, 2007). The drug is highly
eﬀective against the adult worm (as for cestodes), but
has only a minor activity against the larval schisto-
somula. Another class of drugs that show similarities
between Echinococcus and trematodes are the arte-
misinins and synthetic trioxolanes. These anti-
malarial drugs possess a broad spectrum of activity
against trematodes, causing profound damage
in vitro and substantially reducing the worm burden
in experimentally infected mice (reviewed by Keiser
and Utzinger, 2007a, b). Echinoccoccus metacestodes
were also susceptible to artesunate and dihydro-
artemisinin in vitro, while the schistosomula were
found to be particularly susceptible to artemether
and artesunate (Utzinger et al. 2002; Spicher et al.
2008b). The promising activity of meﬂoquine,
another anti-malarial drug, in mice experimentally
infected with S. japonicum and S. mansoni, has been
reported (Keiser et al. 2009), and recent studies in
our laboratory also revealed that meﬂoquine has a
profound impact on in vitro culturedE. multilocularis
metacestodes (A. Hemphill et al. unpublished ob-
servations).
On the other hand, albendazole and mebendazole,
the main anti-echinococcal drugs, have no impact on
S. mansoni (Schmidt, 1998). In contrast, ﬂubend-
azole, a mebendazole-derivative, was active against
S. mansoni in experimentally infected mice (Nessim
et al. 2000; Williams et al. 2003), and another
benzimdazole, triclabendazole, was active against
Fasciola hepatica (Robinson et al. 2001). As for
Echinococcus, F. hepatica was susceptible to nitaz-
oxanide treatment in vitro, and clinical studies
showed that nitazoxanide could be used for the
treatment of fasciolasis in children and adults (re-
viewed in Hemphill et al. 2006).
WHERE TO GO FROM HERE?
As outlined in this review, considerable eﬀorts
have been undertaken to improve the therapeutic
options for the treatment of CE and AE (reviewed
in Vuitton, 2009). These eﬀorts have largely concen-
trated on the establishment of procedures on how
to manage the diseases and by setting up guidelines
for treatment and classiﬁcations of disease status.
Although most successful to a large extent, the cur-
rent benzimidazole-based chemotherapy is far from
optimal and, owing to the limited eﬃcacy of this class
of compounds, their side-eﬀects and their costs,
alternative drugs or drugs that could be integrated
into a combination treatment are clearly needed.
Thus, considerably more input and support is
needed from academic institutions as well as pharma-
ceutical and biotechnological industries and govern-
mental agencies to provide solutions for these
neglected diseases. A recent survey on the ﬁnancial
resources going into research and development
funding in 2007 has shown, that HIV/AIDS received
1.1 billion US dollars, malaria and tuberculosis
obtained over 400 million US dollars each, and
kinetoplastid diseases and diarrhoeal diseases were
granted over 125 and 114million dollars each. On the
other hand, helminth infections as a whole, encom-
passing nematodes, cestodes and trematodes, re-
ceived only 51.6 million dollars (Voelker, 2009).
But ﬁnances alone will not provide novel possi-
bilities. Until recently, Echinococcus drug discovery
has been based on rather anecdotal reports, where
a limited number of drugs belonging to a certain
compound class have been investigated. However,
the Echinococcus drug discovery process has been
lacking several important aspects that are compul-
sary for successfully identifying the best and most
interesting compounds. First, we need to gain access
to comprehensive compound libraries, and we need
to be able to screen these libraries. This can only
be done through the implementation of easy-to-
handle and reliable medium-to-high-throughput in
vitro assays that allow screening of larger numbers of
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anti-parasitic drugs in an eﬃcient manner. Pre-
ferentially, these assays do not rely on subjective
microscopic evaluation, but on objective criteria,
such as speciﬁc markers (e.g. enzyme activities) that
indicate parasite viability/intactness or non-viability/
damage, and which could be detected preferentially
in an (at least) semi-automated system. The devel-
opment of such assays is ongoing, but should be
intensiﬁed.
Secondly, large-scale drug screening activities
are only possible if suﬃcient numbers of parasite
organisms can be generated in vitro. This prerequi-
site has been fullﬁlled due to the pioneering work of
Brehm and co-workers (see Spiliotis and Brehm,
2008), who developed an E. multilocularis metaces-
tode in vitro culture system that allows the generation
of massive numbers of metacestodes out of a rela-
tively small quantity of parasite tissue. This does not
only enable researchers to carry out numerous drug-
screening assays, but also provides the basis for bio-
chemical studies, including the identiﬁcation of drug
targets for speciﬁc compounds by aﬃnity chroma-
tography and mass spectrometry-based sequencing.
Thirdly, it is important to have access to genomic
and EST databases. In 2008, shotgun sequencing
of the E. multilocularis genome was completed
(http://www.sanger.ac.uk/Projects/Echinococcus/).
This opens the door for increased use of in silico
approaches for drug target identiﬁcation, similar to
the discovery of the anti-metacestodicidal activity
of clarithromycin reported by Mathis et al. already
in 2005. In addition, the availiability of a genome
database permits drug target identiﬁcation by
aﬃnity chromatography of parasite extracts on drug-
coupled matrices and subsequent protein identiﬁ-
cation by mass spectroscopy (Mu¨ller et al. 2008a, b).
Furthermore, a system is required to verify puta-
tive drug targets and investigate their functional
role, preferentially by genetic means, such as over-
expression or silencing of genes of interest. The basis
for this was set in 2008, when a method for the
long-term in vitro cultivation and proliferation
of primary cells isolated from axenically grown
E. multilocularis metacestodes was established by
Spiliotis et al. (2008). Isolated E. multilocularis cells
were transiently transfected with a plasmid carrying
the gene coding for the cyano-ﬂuorescent-protein
(CFP), and the corresponding gene product was
expressed and detected by Western blot analysis.
When co-cultured with hepatocytes, cultured E.
multilocularis cells form aggegates, and eventually
undergo complete in vitro regeneration of meta-
cestode vesicles. Prospectively, this could well lead
to the development of transgenic larval stages, and
even adult E. multilocularis worms, and genetic tools
can be exploited to elucidate the exact functional
role of putative drug targets in diﬀerent stages of
development (reviewed in Brehm and Spiliotis,
2008a).
Finally, the in vitro activity of a compound that
exhibits outstanding performance can be veriﬁed
in vivo, initially preferentially in a relevant small
laboratory animal model. The murine or gerbil
models for primary and secondary AE (Stettler et al.
2004; Reuter et al. 2006) represent reliable tools for
such in vivo studies.
CONCLUSIONS
Approximately 2 billion helminth infections occur
in humans worldwide, and these involving the
larval stages of the three cestodes E. multilocularis,
E. granulosus and T. solium are among the most
serious and life-threatening ones (Brehm et al. 2006).
From a practical point of view, the E. multilocularis
model, in contrast to other cestodes, clearly fulﬁlls
the criteria that would allow for intensiﬁed drug-
screening processes. It displays advantages such as
rapid growth and proliferation in vitro, access to
comprehensive genomic information and EST-
databases, the possibility tomaintain parasite isolates
routinely in laboratory mice, and to verify in vitro
results in a relevant in vivo model. Currently, the
monitoring of therapy eﬀectiveness in humans is
based methods based on PET scan using 18F-deoxy-
glucose (Reuter et al. 2004). After optimization, such
methods could be used for the follow-up of suitable
drug candidates in mice or gerbils thereby further
reducing the number of animals per study. Com-
pounds that not only act parasitostatic but also
parasitocidal against Echinococcus in vivo have not
been discovered to date, but it is conceivable that
such compounds exist, and that they would be a very
useful addition to the arsenal of anti-parasitic drugs
against cestodes and trematodes.
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